Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators
申请人:Arrhenius Thomas
公开号:US20100016259A1
公开(公告)日:2010-01-21
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
The synthesis of a series of the title compounds is described applying the addition of 3-pyridyllithium to appropriate trifluoromethylalkanones (path 1) and addition of lithiumorganyls to 2,2,2-trifluoro-1-(3-pyridyl)-ethanone (path 2), respectively.